A Study of the Safety and Efficacy of Infliximab in Patients With Psoriasis

• Status: Completed
• Trial end date: 2004-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if infliximab (anti-TNF) is effective in the treatment of plaque psoriasis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Centocor, Inc.
• Treatments: Infliximab

Criteria

Inclusion Criteria:

• Patients who have had a diagnosis of plaque-type psoriasis for at least 6 months

• Patients who have plaque-type psoriasis covering at least 10% of the body

Exclusion Criteria:

• Patients must not have nonplaque forms of psoriasis

• Patients must not have current drug-induced psoriasis

• Patients must not be pregnant, nursing, or planning pregnancy (both men and women) within 18 months of enrollment

• Patients must not have had any previous treatment with infliximab or any therapeutic agent targeted at reducing TNF